Tissue Diagnostics Market By Product (Consumables (Antibodies, Kits, Reagents, Probes), Instruments(Slide-staining Systems, Scanners, Tissue-processing Systems, Other Instruments)), By Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, Other Diseases), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
Tissue Diagnostics Market Market size is expected to be worth around USD XX Bn Bn by 2032 from USD XX Bn Bn in 2022, growing at a CAGR of XX% during the forecast period from 2023 to 2032.
The tissue diagnostics market encompasses a crucial field in medical science, dedicated to analyzing tissue samples for diagnosis and treatment. This sector plays a vital role in providing personalized healthcare solutions globally. Technological advancements have fueled significant growth and innovation in this market, with cutting-edge techniques transforming disease diagnosis, yielding faster and more precise results.
One standout innovation is molecular diagnostics, enabling the detection of genetic markers within tissues, particularly beneficial for early cancer diagnosis. This molecular-level examination has revolutionized diagnostics, leading to improved patient outcomes. Investments from pharmaceutical companies, hospitals, and research institutions underscore the importance of tissue diagnostics in enhancing patient care and informed treatment decisions.
Tissue diagnostics finds diverse applications in oncology, infectious diseases, immunology, and dermatology. It aids in identifying disease markers, allowing for timely intervention and targeted therapies. Furthermore, tissue diagnostics offers valuable insights into disease progression and treatment monitoring. Industries worldwide are investing in tissue diagnostics, from pharmaceutical companies identifying drug targets to biotechnology firms understanding disease mechanisms, and driving medical advancements.
The tissue diagnostics market is driven by factors like the increasing prevalence of chronic diseases, an aging population, and the demand for personalized medicine. As disease burdens rise globally, the need for accurate diagnostics becomes paramount. Tissue diagnostics empowers clinicians to make well-informed decisions, potentially saving lives and reducing healthcare costs. Responsible practices, transparency, and adherence to ethical standards are essential in maintaining patient trust and regulatory compliance.
Beyond healthcare, tissue diagnostics also finds applications in the business world. Retailers, for instance, can utilize it to analyze customer preferences and tailor offerings accordingly, enhancing customer satisfaction and loyalty. Looking ahead, the tissue diagnostics market is poised for further growth and innovation. Advancements in artificial intelligence and machine learning hold immense potential for automating tissue sample analysis, improving efficiency and accuracy. Integration with telemedicine can extend quality healthcare access, particularly in remote areas.
Rising Cancer Incidence
The global surge in cancer cases is a growing concern, impacting millions of lives worldwide. This escalating cancer incidence has heightened the demand for precise and efficient diagnostic tools. Consequently, there is an increasing need for effective tissue diagnostics, which are instrumental in the early detection, diagnosis, and treatment of various cancer types. As the number of cancer cases continues to rise, the tissue diagnostics market is poised for significant growth.
Empowering Personalized Medicine
Personalized medicine has revolutionized healthcare, tailoring treatment plans based on an individual's unique genetic profile, lifestyle, and environmental factors. Tissue diagnostics play a pivotal role in this paradigm by furnishing precise insights into a patient's tumor characteristics, allowing healthcare providers to discern the most suitable therapeutic interventions. With the evolution of genomic sequencing technologies, tissue diagnostics has become an indispensable tool in the era of personalized medicine.
Technological Strides in Imaging
Recent years have witnessed remarkable advancements in imaging technologies, markedly enhancing the accuracy and efficiency of tissue diagnostics. From conventional methods like histopathology to more sophisticated techniques such as immunohistochemistry and molecular diagnostics, imaging technologies have paved the way for precise diagnosis and prognosis of various diseases. These technological strides not only enhance patient outcomes but also furnish healthcare professionals with valuable insights for tailoring personalized treatment strategies.
Aging Population's Impact
The global demographic landscape is undergoing a significant shift toward an aging population. With this demographic transition comes an elevated risk of developing chronic diseases, including cancer. As the older population continues to expand, the demand for tissue diagnostics is anticipated to surge. Aging individuals often necessitate more frequent screenings and diagnostic tests, cementing tissue diagnostics as an integral component of their healthcare journey. Consequently, the tissue diagnostics market is well-positioned to benefit from the growing aging population.
High Equipment Costs
In the dynamic field of tissue diagnostics, a major challenge for stakeholders is the substantial cost of cutting-edge equipment. The growing demand for precise tissue analysis tools has driven up expenses considerably. Sophisticated imaging systems, advanced molecular analysis tools, and automated tissue processing platforms, while enhancing diagnostic accuracy, often carry steep price tags. This financial burden can strain laboratories and healthcare institutions. This issue is particularly acute for smaller diagnostic labs in underserved areas, limiting their access to state-of-the-art diagnostic capabilities.
Limited Access to Advanced Diagnostics
One major obstacle in the tissue diagnostics market is the restricted availability of advanced diagnostic tools. Despite the growing need for precise diagnoses and personalized treatment strategies, not all healthcare facilities, especially those in remote or less developed areas, can access the latest diagnostic technologies. Disparities in resource allocation and infrastructure hinder numerous patients from reaping the benefits of modern tissue diagnostics. In areas with limited access to advanced diagnostics, healthcare professionals often resort to traditional methods that may not provide the best results. This poses challenges in achieving accurate diagnoses, potentially resulting in misdiagnoses or delayed treatment decisions. Addressing this issue of limited access to advanced diagnostics is essential to ensure equitable healthcare services on a global scale.
Regulatory Compliance Challenges
Tissue diagnostics face significant challenges related to regulatory compliance, impacting various aspects of this market, from tool development to their use. Meeting stringent regulations is a time-consuming and costly endeavor for both manufacturers and healthcare institutions. It involves acquiring approvals, and certifications, and maintaining quality standards, which demand thorough documentation, rigorous testing, and meticulous validation. These processes increase overall expenses and timeframes for product launches. Non-compliance can result in delays or complete halts in product offerings, impeding progress in tissue diagnostics.
Sample Quality Control
The accuracy of diagnoses relies heavily on the quality of tissue samples obtained during biopsies or surgeries, but maintaining sample quality is a major challenge in the field of tissue diagnostics. Various factors, such as inadequate preservation, mishandling during transport, and improper storage, can compromise the integrity of these samples. These variations can lead to incorrect results and misinterpretations by pathologists, ultimately affecting patient care. To mitigate these risks, it's crucial to establish standardized protocols for sample collection, preservation, and transport. Investing in healthcare professional training and implementing quality control guidelines can substantially enhance the accuracy and dependability of tissue diagnostic outcomes.
Empowering the Future of Tissue Diagnostics
In the ever-evolving landscape of tissue diagnostics, it's essential to address these challenges to maintain progress. Collaboration among governments, regulatory bodies, healthcare institutions, and manufacturers is key. To tackle high equipment costs, stakeholders should explore innovative cost-sharing models and leasing options, while partnering with industry leaders and research institutions for more affordable diagnostic technologies. Bridging the access gap necessitates strategic investments in healthcare infrastructure, extending advanced diagnostics to underserved areas. Streamlining global regulatory processes through collaboration among regulatory bodies is crucial. Ensuring sample quality involves education, quality assurance programs, and stringent standards to guarantee accurate diagnostic results.
Breast cancer holds a prominent position within the tissue diagnostics market due to its global impact on women's health. With millions affected worldwide, the segment has seen significant growth, driven by the rising prevalence of breast cancer and advancements in diagnostic techniques. Emerging economies, experiencing economic development, have improved healthcare infrastructure and access to diagnostic services, leading to increased adoption of breast cancer diagnostics. Greater awareness of early detection and advanced technologies further bolster this segment's dominance in the market.
Consumer attitudes have evolved towards breast cancer diagnostics, emphasizing proactive health management and early detection. Increasing breast cancer incidence and success stories of survival have empowered individuals to prioritize their health. Consequently, there's a growing demand for precise and dependable breast cancer diagnostic tests.
Several factors contribute to the expected rapid growth of the breast cancer segment in the tissue diagnostics market. The global burden of breast cancer is increasing, creating a high demand for effective diagnostic tools. Technological advancements, including molecular diagnostic tests, enhance the accuracy of breast cancer detection, further driving demand. Ongoing research and development may introduce innovative diagnostic techniques, potentially revolutionizing breast cancer detection and treatment. These factors collectively fuel the fastest growth rate of the breast cancer segment in the coming years.
End User Analysis
Hospitals are a pivotal component of healthcare services, particularly in tissue diagnostics. The tissue diagnostics market predominantly caters to hospitals as the primary end users due to their extensive infrastructure, presence of skilled healthcare professionals, and advanced diagnostic equipment. These factors make hospitals the preferred choice for patients seeking diagnostic tests. Emerging economies' economic development has significantly impacted the healthcare sector, leading to well-equipped hospitals in these regions. This has improved accessibility to diagnostic services and consequently strengthened the hospitals' dominance in the tissue diagnostics market.
Consumers favor hospitals as trusted institutions for healthcare services, offering a wide range of healthcare services under one roof. This convenience factor, combined with the availability of cutting-edge diagnostic technologies, has influenced consumer behavior and cemented the hospitals' position in the tissue diagnostics market. Hospitals are expected to exhibit the fastest growth rate in the tissue diagnostics market due to the increasing global burden of diseases, advancements in medical technology, and their role as referral centers, attracting patients from primary care providers and other healthcare facilities. Additionally, the trend of medical tourism has contributed to the rapid growth of the hospital segment in the tissue diagnostics market.
With more patients turning to hospitals for diagnostic services, the demand for tissue diagnostics is poised for significant growth in the coming years. This growth is driven by the need for efficient and reliable diagnostic services, the influx of patients to hospitals, and the rise of medical tourism. Hospitals remain at the forefront of providing comprehensive healthcare solutions, making them a central player in the tissue diagnostics market's expansion.
Immunohistochemistry (IHC) plays a dominant role in the tissue diagnostics market, offering a powerful technique for pinpointing specific proteins within tissues. This capability greatly aids in diagnosing and characterizing various diseases. Its versatility spans different disease domains, making it the preferred choice among consumers. The economic development in emerging economies has significantly bolstered the adoption of IHC in tissue diagnostics. Improved economic conditions have led to the establishment of specialized laboratories equipped with IHC technology, enhancing accessibility to immunohistochemistry services in these regions.
Consumer preference for immunohistochemistry in tissue diagnostics is driven by its exceptional reliability and accuracy in disease diagnosis. IHC's ability to identify specific proteins and biomarkers within tissues enables precise disease characterization, facilitating personalized treatment plans. As consumers become more informed about the benefits of targeted therapies and personalized medicine, the demand for immunohistochemistry in the tissue diagnostics market continues to grow.
The immunohistochemistry segment is poised for rapid growth in the tissue diagnostics market due to several factors. Firstly, the rising prevalence of complex diseases, particularly cancer, underscores the need for advanced diagnostic techniques like IHC. This technique's capability to identify disease-associated proteins contributes to accurate diagnoses and personalized treatment plans. Secondly, ongoing research and development in immunohistochemistry are anticipated to uncover novel biomarkers, expanding IHC's applications in disease diagnosis. These advancements are expected to drive growth in the immunohistochemistry segment. Lastly, the increasing emphasis on precision medicine, where treatment plans align with individual patient characteristics, further fuels the demand for immunohistochemistry in the tissue diagnostics market. As personalized medicine gains prominence, the immunohistochemistry segment is projected to exhibit the fastest growth rate in the coming years.
Key Market Segments
- Slide-staining Systems
- Tissue-processing Systems
- Other Instruments
- Breast Cancer
- Gastric Cancer
- Prostate Cancer
- Non-small Cell Lung Cancer
- Other Diseases
By End User
- Pharmaceutical Companies
- Research Laboratories
- Contract Research Organizations
- Other End Users
- In Situ Hybridization
- Digital Pathology and Workflow
- Special Staining
Digital Pathology Solutions Revolutionizing Tissue Diagnostics
Digital pathology solutions have emerged as a game-changer in the field of tissue diagnostics. This innovative technology allows pathologists to digitize and analyze microscopic slides, enhancing efficiency, accuracy, and collaboration. With digital pathology, pathologists can remotely access, annotate, and share slides, facilitating consultations with experts across the globe. The integration of AI and machine learning algorithms further augments the capabilities of digital pathology, enabling automated analysis, pattern recognition, and detection of subtle abnormalities that might go unnoticed by human eyes.
Unveiling New Horizons through Biomarker Discovery
Biomarkers play a crucial role in the diagnosis, prognosis, and treatment selection for various diseases, including cancer. The tissue diagnostics market is experiencing significant growth due to the increasing focus on biomarker discovery. Researchers are relentlessly working to identify specific biomarkers that can serve as reliable indicators of disease presence, progression, and response to therapy. The development of novel biomarkers has the potential to revolutionize personalized medicine, enabling targeted therapies that yield improved patient outcomes.
Companion Diagnostics: Precision Medicine at its Best
The rise of precision medicine has created a fertile ground for companion diagnostics in the tissue diagnostics market. Companion diagnostics refer to diagnostic tests that are essential for the safe and effective use of a specific therapeutic product. By identifying patients who are most likely to benefit or experience adverse reactions from a particular treatment, companion diagnostics enable personalized medicine and enhance the success rate of therapies. As pharmaceutical companies continue to invest in the development of targeted therapies, the demand for companion diagnostics is poised to expand rapidly.
Integration of AI and Machine Learning: A Powerful Force
Artificial intelligence (AI) and machine learning (ML) are reshaping the landscape of tissue diagnostics. The integration of AI and ML algorithms empowers pathologists by augmenting their capabilities and streamlining diagnostic workflows. AI algorithms can analyze vast amounts of data, identify patterns, and detect subtle features that may contribute to disease diagnosis and prognosis. Machine learning algorithms continuously learn from data, evolving their accuracy and performance over time. Combined, AI and ML are revolutionizing tissue diagnostics by providing faster, more accurate, and more consistent results.
Liquid Biopsies for Cancer Detection
Liquid biopsies have revolutionized cancer detection, providing a non-invasive alternative to traditional tissue biopsies. This innovative method involves analyzing circulating tumor cells, cell-free DNA, and exosomes found in bodily fluids, enabling early cancer detection, treatment monitoring, and minimal residual disease detection. This eliminates the need for invasive procedures, making monitoring easier for patients. Additionally, liquid biopsies offer a broader view, allowing doctors to detect and monitor various cancer types simultaneously, capturing tumor diversity effectively. With ongoing research enhancing their sensitivity and specificity, the transformative impact of liquid biopsies in cancer diagnostics cannot be overstated.
The tissue diagnostics market is undergoing a significant transformation with the introduction of multiplex immunohistochemistry (IHC). Traditional IHC has long been a valuable tool for understanding protein expression in tissue samples, but its limitation to visualizing one protein at a time posed challenges for comprehensive analysis. Multiplex IHC has changed the game by enabling the simultaneous visualization of multiple proteins within a single tissue sample. This innovative technique employs specific antibodies labeled with different fluorophores or chromogens, providing a clearer and more in-depth understanding of complex protein expression patterns related to diseases. This enhanced level of information contributes to more precise diagnoses, prognoses, and the selection of targeted therapies, ultimately enhancing patient outcomes.
Telepathology services are transforming the tissue diagnostics market with the help of digital technology. These services utilize telecommunication to enable pathologists to remotely interpret and consult on pathology slides and images. This innovative approach breaks down geographical barriers, facilitating collaboration and reducing diagnostic delays. Furthermore, telepathology services are a boon for underserved regions, where pathology expertise is scarce, improving patient care. They also support medical education by allowing remote guidance and mentoring for aspiring pathologists. The digitization of pathology slides not only streamlines processes but also opens doors to the integration of AI algorithms, enhancing diagnostic accuracy and efficiency.
Automation in Tissue Diagnostics
Automation has brought transformative changes to tissue diagnostics, significantly enhancing efficiency, reproducibility, and accuracy. Unlike traditional manual methods, which are time-consuming and prone to human error, automated platforms like tissue processors and digital imaging systems have revolutionized diagnostic workflows. Standardized protocols minimize variability between labs and pathologists, ensuring consistent results. Additionally, automation reduces processing times, leading to quicker diagnoses and treatment decisions. The integration of artificial intelligence and machine learning further augments automation's capabilities, aiding pathologists in data analysis, pattern recognition, and decision-making. This intelligent automation not only streamlines processes but also improves the overall quality of patient care.
In the ever-evolving landscape of healthcare, tissue diagnostics plays a vital role in disease diagnosis and treatment. Tissue diagnostics involves analyzing microscopic biological samples obtained from various sources like biopsies and autopsies. North America has emerged as a frontrunner in the tissue diagnostics market, primarily due to its robust healthcare infrastructure. The region boasts cutting-edge research facilities, renowned hospitals, and advanced laboratories equipped with high-resolution imaging systems and molecular diagnostic techniques. This technological prowess enables healthcare professionals to provide precise diagnoses, ultimately leading to improved patient outcomes.
North America's leadership in tissue diagnostics is further bolstered by its collaborative research and development approach. The region encourages collaborations between academic institutions, medical centers, and biotechnology companies, fostering knowledge exchange and innovation. This collaborative ecosystem enhances the expertise of researchers, encourages interdisciplinary advancements, and expedites the translation of groundbreaking discoveries into clinical practice. Additionally, stringent regulatory frameworks and quality standards in North America, overseen by bodies like the FDA, ensure the safety and accuracy of diagnostic assays. These regulations promote the development of reliable diagnostic methods, establishing trust among healthcare professionals and patients and giving North American companies a competitive edge globally.
North America remains at the forefront of scientific research and clinical trials, driving innovation in tissue diagnostics. The region's universities, research institutes, and healthcare organizations actively engage in pioneering studies, pushing the boundaries of diagnostic accuracy and effectiveness. These research endeavors contribute not only to scientific knowledge but also attract global attention, solidifying North America's leadership position in the field of tissue diagnostics. Moreover, the rising prevalence of chronic diseases, including cancer, cardiovascular disorders, and autoimmune conditions, has increased the demand for tissue diagnostics. North America, unfortunately, faces a substantial burden of these diseases, necessitating precise diagnoses to guide personalized treatment plans.
North America's commitment to the tissue diagnostics market goes hand in hand with its stringent regulatory approach and dedication to quality. Regulatory bodies like the FDA uphold high standards, ensuring the safety and accuracy of diagnostic tests. This commitment to quality not only safeguards the reputation of North American companies but also gives them a competitive advantage in the global tissue diagnostics arena. Moreover, the region has established comprehensive biobanks, advanced genomic profiling techniques, and sophisticated diagnostic methods to address the healthcare challenges posed by chronic diseases. These resources enable healthcare professionals to deliver personalized care, enhancing health outcomes.
The tissue diagnostics market in North America thrives due to the escalating prevalence of chronic diseases, which necessitate precise and timely diagnoses. These conditions include cancer, cardiovascular disorders, and autoimmune diseases, driving the demand for tissue diagnostics. North America has responded to these challenges by developing advanced diagnostic techniques, comprehensive biobanks, and cutting-edge genomic profiling. These resources enable the region to effectively address the healthcare burden imposed by chronic diseases. North America's dominance in the tissue diagnostics market is a testament to its technological prowess, collaborative research environment, and commitment to maintaining high-quality standards in healthcare.
Key Regions and Countries
- The UK
- Rest of Western Europe
- The Czech Republic
- Rest of Eastern Europe
- South Korea
- Australia & New Zealand
- Rest of APAC
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Rest of MEA
Market Share & Key Players Analysis
Roche Diagnostics, a subsidiary of the Swiss pharmaceutical giant Roche, has been a game-changer in tissue diagnostics. Through innovation and extensive research, they've developed a wide range of products to meet healthcare professionals' and patients' diverse needs. Their flagship, the Ventana platform, is a cutting-edge, fully automated staining system, that ensures precise tissue sample analysis for accurate diagnoses. Roche Diagnostics remains committed to pushing the boundaries of tissue diagnostics technology through ongoing R&D investments.
Danaher, a global science and tech conglomerate, excels in tissue diagnostics via its subsidiary, Leica Biosystems. Their comprehensive suite of cancer diagnostic tools provides precise results, aiding clinicians in personalized treatment decisions. Leica Biosystems' Novocastra HD antibodies are renowned for quality and reliability in immunohistochemistry, immunocytochemistry, and molecular pathology. Danaher's commitment to R&D ensures a steady stream of innovative healthcare solutions.
Thermo Fisher Scientific, a leading scientific solutions provider, is a pioneer in molecular pathology within the tissue diagnostics market. Their advanced platforms, like QIAGEN QIAstat-Dx, offer rapid and precise disease and genetic alteration detection. Thermo Fisher Scientific's broad product range includes tissue processors, microtomes, and visualization systems, covering the entire diagnostic workflow. Their focus on accuracy, efficiency, and reliability continues to drive advancements in molecular pathology.
Abbott, a diversified healthcare company, has significantly impacted the tissue diagnostics market through its diagnostics division. Leveraging diagnostic technology expertise, Abbott provides a wide array of products and services for enhanced diagnostic accuracy and efficiency. The ARCHITECT ci systems automate diagnostic testing, ensuring precise sample processing. Abbott's leadership in infectious disease testing platforms and molecular diagnostics has revolutionized tissue diagnostics, enabling clinicians to detect diseases and monitor patient progress more effectively.
Top Key Players in Tissue Diagnostics Market
- Roche Diagnostics
- Thermo Fisher Scientific
- Merck KGaA
- Agilent Technologies
- Dickinson and Company (BD)
- Sakura Finetek Japan Co. Ltd.
- Biogenex Laboratories
- In 2021, Hologic, a well-respected healthcare company, created quite a buzz by acquiring Biotheranostics. This strategic partnership aimed to boost Hologic's ability to analyze cancer's genomic makeup, providing healthcare professionals with deeper insights into the molecular characteristics of cancerous tissues. By integrating Biotheranostics' advanced technologies, the goal was to significantly enhance cancer diagnosis and treatment options.
- In 2020, there was a significant development in the field of tissue diagnostics when Danaher successfully acquired GE's biopharma business. This acquisition allowed Danaher to expand its offerings in diagnostics and life sciences, solidifying its position in the market. The collaboration's increased capabilities promised a wider range of diagnostic solutions, ultimately benefiting both healthcare providers and patients.
- In 2019, Thermo Fisher Scientific introduced the Ion Torrent Genexus, a groundbreaking technology that revolutionized the automated next-generation sequencing of tissue samples. This innovation streamlined the analysis process, leading to faster and more accurate diagnostic results. The launch of the Ion Torrent Genexus marked a new era in tissue diagnostics, greatly enhancing researchers' ability to study genomic information with unparalleled efficiency and precision.
Report Features Description Market Value (2022) USD XX Bn Forecast Revenue (2032) USD XX Bn CAGR (2023-2032) X.X% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product (Consumables (Antibodies, Kits, Reagents, Probes), Instruments(Slide-staining Systems, Scanners, Tissue-processing Systems, Other Instruments))
By Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, Other Diseases)
By End Users (Hospitals, Pharmaceutical Companies, Research Laboratories, Contract Research Organizations, Other End Users)
By Technology (Immunohistochemistry, In Situ Hybridization, Digital Pathology and Workflow, Management, Special Staining)
Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Roche Diagnostics, Danaher, Thermo Fisher Scientific, Abbott, Merck KGaA, Agilent Technologies, Abcam, Becton, Dickinson and Company (BD), Sakura Finetek Japan Co. Ltd., Biogenex Laboratories Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)